Literature DB >> 2006915

Biosynthesis of bone proteins [SPP-1 (secreted phosphoprotein-1, osteopontin), BSP (bone sialoprotein) and SPARC (osteonectin)] in association with mineralized-tissue formation by fetal-rat calvarial cells in culture.

T Nagata1, C G Bellows, S Kasugai, W T Butler, J Sodek.   

Abstract

To determine the relationship between the expression of bone proteins and the formation of mineralized-tissue matrix, the biosynthesis of non-collagenous bone proteins was studied in cultures of fetal-rat calvarial cells, which form mineralized nodules of bone-like tissue in the presence of beta-glycerophosphate. The temporal pattern of protein synthesis in both mineralizing and non-mineralizing cultures was studied by metabolic labelling with [35S]methionine, 35SO4(2-) or 32PO4(3-) over a 5-day period. After a 24 h labelling period, the culture media were harvested and the cell layers extracted sequentially with aq. 0.5 M-NH3, followed by 4 M-guanidinium chloride (GdmCl), 0.5 M-EDTA and a second extraction with 4 M-GdmCl. Protein associated with collagenous bone matrix was analysed after digestion with bacterial collagenase. On the basis of [35S]methionine labelling, the major proteins extracted from the mineralizing matrix were secreted phosphoprotein-1 (SPP-1; osteopontin), bone sialoprotein (BSP) and a 14 kDa phosphoprotein. The presence of SPP-1 and BSP in the conditioned media of both mineralizing and non-mineralizing cultures and their incorporation into the mineralizing nodules indicated that these proteins associate with preformed mineral crystals. However, some BSP was also present in GdmCl extracts and, together with a 35 kDa sulphated protein, was released from a bacterial-collagenase digestion of the tissue residue in both non-mineralizing and mineralizing cultures. Two forms of sulphated SPP-1 were identified, a highly phosphorylated 44 kDa species being the predominant form in the mineralized matrix. The BSP was more highly sulphated but less phosphorylated than SPP-1. Bone SPARC (secreted protein, acid and rich in cysteine) protein (osteonectin) was present almost entirely in the conditioned media and did not incorporate 32PO4(3-) or 35SO4(2-). The SPP-1 and the 14 kDa protein were susceptible to thrombin digestion, the 44 kDa SPP-1 being specifically cleaved into 28 and 26 kDa fragments. The fragments were labelled uniformly with [35S]methionine, but the 28 kDa fragment incorporated more 35SO4(2-), but less 32PO4(3-), than the 26 kDa fragment. These studies demonstrate that SPP-1 and BSP are the major osteoblast-derived bone proteins to bind to the bone mineral. That BSP also binds to the collagenous bone matrix indicates a potential role for this protein in linking the hydroxyapatite with collagen.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2006915      PMCID: PMC1150169          DOI: 10.1042/bj2740513

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  44 in total

1.  Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin.

Authors:  D R Senger; C A Perruzzi; A Papadopoulos; D G Tenen
Journal:  Biochim Biophys Acta       Date:  1989-06-13

2.  Human bone sialoprotein. Deduced protein sequence and chromosomal localization.

Authors:  L W Fisher; O W McBride; J D Termine; M F Young
Journal:  J Biol Chem       Date:  1990-02-05       Impact factor: 5.157

3.  Differentiation of osteoblasts and formation of mineralized bone in vitro.

Authors:  H C Tenenbaum; J N Heersche
Journal:  Calcif Tissue Int       Date:  1982-01       Impact factor: 4.333

4.  Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence.

Authors:  A Oldberg; A Franzén; D Heinegård
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

5.  Isolation and characterization of native adult osteonectin.

Authors:  R W Romberg; P G Werness; P Lollar; B L Riggs; K G Mann
Journal:  J Biol Chem       Date:  1985-03-10       Impact factor: 5.157

6.  Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta.

Authors:  C M Overall; J L Wrana; J Sodek
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

7.  A chemical model for the cooperation of sulfates and carboxylates in calcite crystal nucleation: Relevance to biomineralization.

Authors:  L Addadi; J Moradian; E Shay; N G Maroudas; S Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

8.  Immunohistochemical demonstration of a 44-KD phosphoprotein in developing rat bones.

Authors:  M P Mark; C W Prince; T Oosawa; S Gay; A L Bronckers; W T Butler
Journal:  J Histochem Cytochem       Date:  1987-07       Impact factor: 2.479

9.  Multiple forms of SppI (secreted phosphoprotein, osteopontin) synthesized by normal and transformed rat bone cell populations: regulation by TGF-beta.

Authors:  T Kubota; Q Zhang; J L Wrana; R Ber; J E Aubin; W T Butler; J Sodek
Journal:  Biochem Biophys Res Commun       Date:  1989-08-15       Impact factor: 3.575

10.  Mineral-binding proteoglycans of fetal porcine calvarial bone.

Authors:  H A Goldberg; C Domenicucci; G A Pringle; J Sodek
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

View more
  29 in total

1.  An osteonectin-like protein in the matrix of cultured osteogenic cell-line MC3T3-E1, which is associated with calcification.

Authors:  M Mizuno; H Y Zhou; H Yamada; M Kawamura; H Hirano; Y Kuboki
Journal:  Calcif Tissue Int       Date:  1992-08       Impact factor: 4.333

2.  Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome.

Authors:  Shunji Tomatsu; Adriana M Montaño; Vu Chi Dung; Amiko Ohashi; Hirotaka Oikawa; Toshihiro Oguma; Tadao Orii; Luis Barrera; William S Sly
Journal:  Mol Ther       Date:  2010-03-23       Impact factor: 11.454

Review 3.  Selective drug delivery to bone using acidic oligopeptides.

Authors:  Junko Ishizaki; Yoshihiro Waki; Tatsuo Takahashi-Nishioka; Koichi Yokogawa; Ken-Ichi Miyamoto
Journal:  J Bone Miner Metab       Date:  2008-11-19       Impact factor: 2.626

4.  Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily.

Authors:  H Shiraga; W Min; W J VanDusen; M D Clayman; D Miner; C H Terrell; J R Sherbotie; J W Foreman; C Przysiecki; E G Neilson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

Review 5.  Tissue specific and vitamin D responsive gene expression in bone.

Authors:  C White; E Gardiner; J Eisman
Journal:  Mol Biol Rep       Date:  1998-01       Impact factor: 2.316

6.  Bone-targeting of quinolones conjugated with an acidic oligopeptide.

Authors:  Tatsuo Takahashi; Koichi Yokogawa; Naoki Sakura; Masaaki Nomura; Shinjiro Kobayashi; Ken-ichi Miyamoto
Journal:  Pharm Res       Date:  2008-07-29       Impact factor: 4.200

7.  Involvement of osteopontin as a core protein in craniopharyngioma calcification formation.

Authors:  SongTao Qi; GuangLong Huang; Jun Pan; Jia Li; Xi'An Zhang; LuXiong Fang; BaoGuo Liu; Wei Meng; YongMing Zhang; XiaoJun Liu
Journal:  J Neurooncol       Date:  2009-11-10       Impact factor: 4.130

8.  Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition.

Authors:  Michaël Chaplet; Cédric Detry; Christophe Deroanne; Larry W Fisher; Vincent Castronovo; Akeila Bellahcéne
Journal:  Biochem J       Date:  2004-12-15       Impact factor: 3.857

9.  Bone sialoprotein mRNA expression and ultrastructural localization in fetal porcine calvarial bone: comparisons with osteopontin.

Authors:  J Chen; M D McKee; A Nanci; J Sodek
Journal:  Histochem J       Date:  1994-01

10.  Effect of prostaglandin E2 on mineralization of bone nodules formed by fetal rat calvarial cells.

Authors:  T Nagata; K Kaho; S Nishikawa; H Shinohara; Y Wakano; H Ishida
Journal:  Calcif Tissue Int       Date:  1994-12       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.